Transcutaneous Auricular Vagus Nerve Stimulation and Quality of Recovery After Major Noncardiac Surgery
Launched by PEKING UNIVERSITY FIRST HOSPITAL · May 2, 2025
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment called transcutaneous auricular vagus nerve stimulation (taVNS) to see if it can help patients recover better after major noncardiac surgeries, which are surgeries not related to the heart. Research has shown that taVNS might help with pain, sleep, and recovery from surgery. The goal of this study is to find out if using taVNS during and after surgery can improve how well patients feel and recover.
To participate in this trial, you need to be between 18 and 84 years old and scheduled for a noncardiac surgery expected to last at least two hours. However, certain conditions would exclude you from joining, such as having skin issues on the ear, specific serious medical conditions, or if you are expected to need a breathing machine for more than a day after surgery. If you do join, you can expect to receive the taVNS treatment around the time of your surgery, and researchers will monitor your recovery process closely. This study is not yet recruiting participants, but it aims to provide valuable insights into improving recovery for patients after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged ≥18 years but \<85 years.
- • 2. Scheduled for elective or limited-time noncardiac surgery with expected duration ≥2 hours.
- Exclusion Criteria:
- • 1. Lesions or infections of the auricle skin.
- • 2. Recent or long-term use of cholinergic or anticholinergic medications.
- • 3. Neurosurgery.
- • 4. Expected mechanical ventilation with intubation for ≥1 day after surgery.
- • 5. Diagnosed schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis before surgery.
- • 6. Preoperative left ventricular ejection fraction (LVEF) \<30%, or those with sick sinus syndrome, sinus bradycardia (heart rate \<50 beats per minute), atrioventricular block of grade II or above, or implanted pacemaker.
- • 7. Inability to communicate due to coma, severe dementia, or language barrier before surgery, or unable to cooperate with intervention.
- • 8. American Society of Anesthesiologists physical status grade \>IV, or estimated survival \<24 hours.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Dong-Xin Wang, MD, PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported